Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase

Wong E, Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451–2466 Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422 Reed E (2006) Cisplatin and analogs. In: Cancer chemotherapy and biotherapy. Chap. 14. Lippincott Williams & Wilkins, Philadelphia, pp 332–343 Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1–10 Levi J, Jacobs C, Kalman SM, McTigue M, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213:545–550 Tanaka H, Ishikawa E, Teshima S, Shimizu E (1986) Histopathological study of human cisplatin nephropathy. Toxicol Pathol 14:247–257 Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464 Daugaard G, Abildgaard U (1989) Cisplatin nephrotoxicity: a review. Cancer Chemother Pharmacol 25:1–9 Gemba M, Fukuishi N (1991) Amelioration by ascorbic acid of cisplatin-induced injury in cultured renal epithelial cells. Contrib Nephrol 95:138–142 Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65:307–314 Meijer S, Sleijfer DT, Mulder NH, Sluiter WJ, Marrink J, Koops HS, Brouwers TM, Oldhoff J, van der Hem GK, Mandema E (1983) Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer 51:2035–2040 Offerman JJ, Meijer S, Sleijfer DT, Mulder NH, Donker AJ, Koops HS, van der Hem GK (1984) Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 12:36–38 Weiner MW, Jacobs C (1983) Mechanism of cisplatin nephrotoxicity. Fed Proc 42:2974–2978 Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213:551–556 Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362–1371 Kuhlmann MK, Burkhardt G, Kohler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478–2480 Hanigan MH, Gallagher BC, Taylor PT Jr, Large MK (1994) Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 54:5925–5929 Hanigan MH, Gallagher BC, Taylor PT Jr (1996) Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney. Am J Obstet Gynecol 175:270–274 Zhang L, Hanigan MH (2003) Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 306:988–994 Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R, Lieberman MW (2001) Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol 159:1889–1894 Townsend DM, Hanigan MH (2002) Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300:142–148 Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070–3074 Hanigan MH, Gallagher BC, Townsend DM, Gabarra V (1999) Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 20:553–559 Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, Carretero J, Estrela JM (2005) Acceleration of glutathione efflux and inhibition of gamma-glutamyl transpeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem 280:6950–6959 Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H (2005) Gamma-glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults. Circulation 112:2130–2137 Paolicchi A, Minotti G, Tonarelli P, Tongiani R, De CD, Mezzetti A, Dominici S, Comporti M, Pompella A (1999) Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation: a potential mechanism in atherosclerosis. J Investig Med 47:151–160 Hanigan MH (1998) Gamma-glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis. Chem Biol Interact 111–112:333–342 Hanigan MH, Pitot HC (1985) Gamma-glutamyl transpeptidase: its role in hepatocarcinogenesis. Carcinogenesis 6:165–172 Tate SS, Meister A (1981) Gamma-glutamyl transpeptidase: catalytic, structural and functional aspects. Mol Cell Biochem 39:357–368 Keillor JW, Castonguay R, Lherbet C (2005) Gamma-glutamyl transpeptidase substrate specificity and catalytic mechanism. Methods Enzymol 401:449–467 Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol 257:L163–L173 Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJF (2002) BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 38:1148–1156 Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 25:584–599 Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F (2003) Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol 51:376–384 Hausheer FH, Kochat H, Parker AR, Ding D, Yao S, Hamilton SE, Petluru PN, Leverett BD, Bain SH, Saxe JD (2003) New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 52(Suppl 1):S3–S15 Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJF (2003) Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther 74:157–169 Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, Zegers I, van der Vijgh WJF, Giaccone G (2005) Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. Br J Cancer 92:1636–1643 Hausheer F, Kanter P, Rustum Y, Cao S, Haridas K, Reddy D, Seetharamulu P, Zhao M, Yao S, Pavankumar P, Murali D (1997) Abstract #2089: BNP7787: A novel antitumor potentiating drug which protects against cisplatin and carboplatin toxicities. In: Proceedings of the AACR (88th annual meeting), vol 38, p 311 Hausheer F, Cavaletti G, Tredici G, Oggioni N, Spinelli S, Pezzoni G, Manzotti C, Haridas K, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Cavalletti E (1999) Abstract #2633: Oral and intravenous BNP7787 protects against platinum neurotoxicity without in vitro or in vivo tumor protection. In: Proceedings of the AACR (90th annual meeting), vol 40, p 398 Hausheer FH, Rustum Y, Cao S, Haridas K, Reddy D, Seetharamalu P, Zhao M, Yao S, Pavankumar P, Murali D (1998) Abstract #1077: BNP7787—Administration in vivo results in increased therapeutic index and toxicity reduction of platinum drugs. In: Proceedings of the AACR (89th annual meeting), vol 39, p 158 Shanmugarajah D, Ding D, Huang Q, Chen X, Kochat H, Petluru PN, Ayala PY, Parker AR, Hausheer FH (2009) Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 877:857–866 Shanmugarajah D (2007) Mechanism of action of BNP7787, a novel chemoprotective agent. Dissertation, presented to the University of Texas Health Science Center at San Antonio Ormstad K, Uehara N (1982) Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS Lett 150:354–358 Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJF (2004) Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. Br J Cancer 90:1654–1659 Tate SS, Meister A (1974) Interaction of gamma-glutamyl transpeptidase with amino acids, dipeptides, and derivatives and analogs of glutathione. J Biol Chem 249:7593–7602 Thompson GA, Meister A (1977) Interrelationships between the binding sites for amino acids, dipeptides, and gamma-glutamyl donors in gamma-glutamyl transpeptidase. J Biol Chem 252:6792–6798 Thompson GA, Meister A (1975) Utilization of l-cystine by the gamma-glutamyl transpeptidase–gamma-glutamyl cyclotransferase pathway. Proc Natl Acad Sci USA 72:1985–1988 Forman HJ, Shi MM, Iwamoto T, Liu RM, Robison TW (1995) Measurement of gamma-glutamyl transpeptidase and gamma-glutamylcysteine synthetase activities in cells. Methods Enzymol 252:66–71 Smith GD, Ding JL, Peters TJ (1979) A sensitive fluorimetric assay for gamma-glutamyl transferase. Anal Biochem 100:136–139 Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24:19–38 Jones MM, Basinger MA, Holscher MA (1992) Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundam Appl Toxicol 18:181–188 Alberts DS, Bleyer WA (1996) Future development of amifostine in cancer treatment. Semin Oncol 23:90–99 Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW (1990) Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 10:353–365 Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112 Verschraagen M, Zwiers TH, de Koning PE, Welink J, van der Vijgh WJF (2001) Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 753:293–302 Verschraagen M, van der Born K, Zwiers TH, van der Vijgh WJF (2002) Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 772:273–281 Verschraagen M, Zwiers TH, Torun E, Donker MG, Reinhoud NJ, van der Vijgh WJF (2003) Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector. J Pharm Sci 92:1040–1050 Verschraagen M, Bosma M, Zwiers TH, Torun E, van der Vijgh WJF (2003) Quantification of mesna and total mesna in kidney tissue by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 783:33–42 Verschraagen M, Kedde MA, Hausheer FH, van der Vijgh WJF (2003) The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG. Cancer Chemother Pharmacol 51:499–504 Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJF (2004) Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects. Biochem Pharmacol 68:493–502 Hausheer FH, Kochat H, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Parker A, Hamilton S (2000) Abstract #4890: BNP7787: A novel chemoprotecting agent for platinum and taxane toxicity. In: Proceedings of the AACR (91st annual meeting), vol 41, pp 769–770 Hausheer FH, Kochat H, Zhao M, Hamilton S, Wu M, Seetharamulu P, Petluru P, Huang Q, Chen X, Ma H, Ding D, Leverett B, Wu Y, Wang J, Saxe J, Parker A, Berghorn E (2001) Abstract #1990: BNP7787, A novel neuroprotective agent in taxane and platinum regimens, does not interfere with antitumor activity. In: Proceedings of the AACR (92nd annual meeting), vol 42, p 370 Anders MW, Dekant W (1998) Glutathione-dependent bioactivation of haloalkenes. Annu Rev Pharmacol Toxicol 38:501–537 Dekant W (1993) Bioactivation of nephrotoxins and renal carcinogens by glutathione S-conjugate formation. Toxicol Lett 67:151–160 Dekant W, Vamvakas S, Anders MW (1994) Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate beta-lyase pathway. Adv Pharmacol 27:115–162 Dekant W, Henschler D (1999) Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation. J Cancer Res Clin Oncol 125:174–181 Dekant W (2001) Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation. Toxicol Lett 124:21–36 Okada T, Suzuki H, Wada K, Kumagai H, Fukuyama K (2007) Crystal structure of the gamma-glutamyl transpeptidase precursor protein from Escherichia coli: structural changes upon autocatalytic processing and implications for the maturation mechanism. J Biol Chem 282:2433–2439 Okada T, Suzuki H, Wada K, Kumagai H, Fukuyama K (2006) Crystal structures of gamma-glutamyl transpeptidase from Escherichia coli, a key enzyme in glutathione metabolism, and its reaction intermediate. Proc Natl Acad Sci USA 103:6471–6476 Andersson A, Isaksson A, Brattstrom L, Hultberg B (1993) Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin Chem 39:1590–1597 Kleinman WA, Richie JP Jr (2000) Status of glutathione and other thiols and disulfides in human plasma. Biochem Pharmacol 60:19–29 Shaw IC, Graham MI (1987) Mesna: a short review. Cancer Treat Rev 14:67–86